Skin Cancer Screening: Who Benefits, Done Right

TL;DR: Skin cancer screening is one of the places where the wellness message and the evidence part ways. For an average-risk adult with no symptoms, a yearly head-to-toe skin scan has never been shown in a randomized trial to lower the odds of dying from melanoma, and in 2023 the US Preventive Services Task Force again graded that evidence insufficient. At the same time, melanoma diagnoses have risen roughly sixfold in forty years while deaths stayed close to flat, which points to a large amount of overdiagnosis: thin and in-situ lesions found and removed that were never going to threaten a life. The recent fall in melanoma deaths tracks with better immunotherapy rather than with more screening. None of that means skin cancer is harmless or that checking is pointless. It means the value of a skin exam depends on your risk. If you have fair skin that burns, many moles or unusual ones, a personal or family history of melanoma, or you take immune-suppressing medication, a dermatologist exam and often total-body photography make sense. If you are average risk, the highest-yield moves are learning the ABCDE and ugly-duckling warning signs, watching for anything new or changing, protecting your skin from ultraviolet light, and staying out of tanning beds. Phone apps that claim to read your mole and at-home gene stickers that claim to rule out melanoma are not reliable enough to trust and do not replace a biopsy.

Does everyone need a yearly full-body skin check?

The short answer is no, at least not on the strength of the evidence. It is common to hear that every adult should get an annual skin screening the way we screen for colon or breast cancer. For average-risk people with no symptoms, that recommendation runs ahead of what has been proven.

In 2023 the US Preventive Services Task Force reviewed the evidence and issued an "I" statement, meaning the current evidence is insufficient to weigh the benefits and harms of a clinician doing a visual skin exam to screen asymptomatic teens and adults.¹ That is the same conclusion it reached in 2016. The plain reason behind it is that no completed randomized trial has shown that screening lowers melanoma deaths. The Task Force was careful to say this does not apply to someone with a suspicious spot or to people already known to be high risk; those are different situations that call for a look. It applies to the idea of scanning everyone, every year, as a default.

People often point to Germany, where a large screening program in one region reported a drop in melanoma deaths after 2003. That early signal did not hold. Follow-up analysis found that melanoma death rates in the region returned to where they started within a few years, and that the temporary dip lined up with a temporary rise in deaths coded to vaguely defined causes, which suggests the improvement was a coding artifact rather than lives saved.⁷ It is a useful caution against reading too much into a single hopeful number.

Why are melanoma diagnoses rising if deaths are not?

This is the part that reframes the whole topic. Over the past four decades, the number of melanomas diagnosed in the United States has risen roughly sixfold, yet the death rate barely moved for most of that period.² When diagnoses climb steeply and deaths do not follow, the most likely explanation is overdiagnosis: we are finding and treating many lesions that meet the microscope definition of melanoma but were never destined to spread or shorten a life.

You can see the fingerprint of this in the numbers. In-situ melanoma, the earliest and least dangerous form confined to the top layer of skin, is now diagnosed almost as often as invasive melanoma. More inspection, a lower threshold to biopsy, and a lower threshold for the pathologist to call a borderline spot melanoma all push the count up without changing how many people the disease kills. Researchers who study this have called melanoma a leading example of cancer overdiagnosis.²

Two honest caveats keep this from tipping into complacency. First, melanoma is a serious cancer; a thick one that has grown down into the skin can spread and kill, and those cases are the ones that matter most. Second, the recent and welcome decline in melanoma deaths is driven mostly by dramatic advances in treatment, the immunotherapy and targeted drugs that changed the outlook for advanced disease, rather than by finding more thin spots earlier. The lesson is not to ignore your skin. It is to aim screening where the risk of a dangerous cancer is highest, and to understand that removing every faint freckle earlier is not the same as saving lives.

Who is at high risk?

Screening earns its place when your baseline risk is high enough that a careful exam is likely to find something that matters. Risk is not evenly spread, and knowing where you sit changes what you should do. The strongest and most consistent risk factors, drawn from a large body of pooled research, are these.⁶

• Atypical moles. Having several atypical, or dysplastic, moles is the single strongest common risk marker, raising melanoma risk severalfold. The count of ordinary moles matters too: someone with more than a hundred moles carries several times the risk of someone with a handful.
• Fair, sun-sensitive skin. Red hair, light eyes, skin that burns instead of tans, and heavy freckling all raise risk, with red hair carrying roughly triple the baseline. These reflect how little natural pigment protection the skin has.
• A personal history of skin cancer. A prior melanoma markedly raises the chance of a second one, and a history of basal or squamous cell skin cancer signals the kind of sun damage that also raises melanoma risk.
• Family history and inherited genes. A melanoma in a first-degree relative roughly doubles risk. A smaller group of families carry an inherited change in a gene called CDKN2A, which drives many atypical moles and a high lifetime melanoma risk, sometimes alongside pancreatic cancer. Gene testing belongs with that kind of strong family pattern rather than with general prevention.
• A suppressed immune system. People on long-term immune-suppressing medication, above all organ-transplant recipients, have sharply higher skin cancer risk, mostly the squamous and basal cell types but melanoma as well.
• Sunburns and tanning beds. A history of blistering sunburns, and any use of indoor tanning, raises risk in a dose-dependent way, with the largest effect when tanning starts young.

If several of these describe you, a dermatologist exam and a structured surveillance plan are reasonable. If none do, the yield of scanning falls, and the everyday warning signs and prevention below carry more of the weight.

What does screening done well look like?

Good screening is less about frequency and more about method and attention. A few pieces do the heavy lifting.

Know your own skin. The ABCDE guide is a starting point for what a worrisome mole looks like: Asymmetry, Border irregularity, Color that varies within the spot, Diameter larger than a pencil eraser, and Evolving, meaning any change in size, shape, or color over time. The most telling sign is often the last one, change, together with the "ugly duckling" idea: the spot that stands out because it looks unlike your other moles. ABCDE is not perfect and misses some melanomas, including the fast-growing raised kind and colorless ones, so the rule of thumb that beats any checklist is simple: anything new, changing, or different from its neighbors deserves a look.

A trained clinician exam, with dermoscopy. When a clinician examines the skin, a handheld tool called a dermatoscope, which lights and magnifies the lesion, meaningfully improves accuracy in trained hands. Pooled data put sensitivity for melanoma near 90 percent with dermoscopy versus about 71 percent with the naked eye, without giving up specificity.⁴ The catch is the phrase "trained hands": in untrained users the same tool can lower accuracy, so the skill of the examiner is the deciding factor.

Total-body photography for people with many moles. For someone with a high mole count or atypical-mole syndrome, mapping the skin with standardized photographs, and comparing over time, helps in two directions at once. It catches the mole that is changing against its own baseline, and it prevents needless surgery by proving that stable moles are stable. It is a surveillance aid for high-risk skin rather than a test for the average person. A more specialized imaging method, reflectance confocal microscopy, can give a near-microscope view of a questionable spot in expert clinics and spares some unnecessary excisions, but it is a specialist tool.

Can an app or an at-home test check my moles?

This is where the technology story gets oversold, and where being careful protects you. The appetite for a phone that reads your skin is understandable, but the tools are not there yet.

Smartphone apps that claim to assess a mole from a photo have been studied, and the results are poor. A systematic review of these apps found low-quality evidence and sensitivity that swung wildly from one app to the next, some missing the large majority of cancers.⁵ No consumer phone app is cleared by the FDA to diagnose melanoma, and regulators have taken action against apps that claimed to detect it. An app that misses a melanoma while telling you it looks fine is worse than no app, because false reassurance can delay the visit that would have caught it.

The more serious progress is happening in the clinic rather than the app store. Artificial-intelligence systems that help triage skin lesions inside a supervised medical pathway have earned regulatory marks in Europe and a conditional, evidence-gathering endorsement in the UK's health service. Those are clinician-facing triage tools inside a regulated referral system, working alongside a specialist, and they have not been shown to lower deaths. They are a long way from a phone deciding, at home, that your mole is safe.

At-home molecular tests deserve the same caution. An adhesive patch that lifts skin cells from a suspicious spot and checks two genes is marketed as a way to rule melanoma out. Its reported ability to correctly reassure is high only when the pre-test odds of cancer are already low, and its specificity is modest, so many flagged spots still end in a biopsy. It does not replace the microscope on a spot that looks worrisome. The company behind the best-known version filed for bankruptcy in 2024, which is its own comment on how settled this technology is. The prognostic gene tests offered after a melanoma is diagnosed sit in a similar place: the major dermatology and cancer-network guidelines do not endorse using them to steer treatment, out of concern they drive overtreatment without proven benefit.

What lowers your risk?

The strongest evidence in this whole area is not about finding melanoma; it is about not getting it. Ultraviolet light is the main changeable cause of melanoma and of the far more common basal and squamous cell skin cancers, which is where the Task Force itself points as the better-supported path.

Sun protection is the lever. The best trial evidence comes from an Australian randomized study in which adults assigned to daily sunscreen use developed fewer melanomas over the following decade than those left to use it at their discretion, with the strongest effect on invasive melanoma.³ It is a single trial with modest numbers, so the fair way to say it is that the best available evidence supports daily sun protection, alongside shade, clothing, and hats, as a way to lower melanoma risk. Tanning beds sit at the opposite end: the World Health Organization's cancer agency classifies ultraviolet tanning devices as a top-tier human carcinogen, in the same group as tobacco, and starting before age 35 raises melanoma risk by roughly three-quarters. There is no version of a tanning bed that is a healthy source of vitamin D; if your vitamin D is low, a supplement is the answer.

Does darker skin mean I do not need to worry?

No, and this belief is dangerous. Melanoma is much less common in people with brown and Black skin, but when it appears it is often found later and is more often fatal.⁸ Part of that is a false sense of safety, on the part of patients and clinicians alike, that delays the diagnosis.

The subtype that disproportionately affects people with darker skin is acral melanoma, which shows up on the palms, the soles of the feet, and under the nails, and it is not driven by sun exposure. Because those are easy places to overlook, the practical message is to include them: check the soles, the spaces between the toes, the palms, and the nail beds for a new dark streak or spot. Skin of color is not a free pass; it changes where to look, not whether to look.

Guidance from the Clinic

"The version of this I want to correct is the idea that a yearly full-body scan for everyone is settled, high-value medicine. It is not, and the evidence has said so for years. What I do instead is spend a few minutes figuring out where a person sits. If you have fair skin that burns, a scatter of odd-looking moles, a melanoma in the family, or you are on an immune-suppressing drug, I want you seeing dermatology and often getting your moles photographed, because for you a careful exam can find something that matters. If you are average risk, I would rather teach you the ugly-duckling sign, tell you to flag anything new or changing, and get you serious about sun protection and no tanning beds, which is the part with the best proof behind it. And I am blunt about the gadgets: a phone app is not going to keep you safe, and a spot that looks wrong needs a biopsy rather than a sticker. My job is to point the attention where the risk is rather than scanning everyone and calling it prevention."

Related at Fishtown Medicine

• Early Cancer Detection: A Medicine 3.0 Approach - where skin screening fits a fuller early-detection plan
• The Galleri Multi-Cancer Blood Test - a liquid biopsy that looks for many cancers at once, and its limits
• Full-Body MRI Screening - what whole-body imaging can and cannot find
• PSA and Prostate Cancer Screening - another screening test where overdiagnosis is the central question
• Colorectal Cancer Screening: Colonoscopy vs Cologuard vs FIT - a screen where the mortality benefit is well proven, for contrast
• Lung Cancer Screening: Who Needs a Low-Dose CT - the same risk-based logic, applied to the lungs

Scientific References

1. US Preventive Services Task Force. "Screening for Skin Cancer: US Preventive Services Task Force Recommendation Statement." JAMA. 2023;329(15):1290-1295.
2. Welch HG, Mazer BL, Adamson AS. "The Rapid Rise in Cutaneous Melanoma Diagnoses." New England Journal of Medicine. 2021;384(1):72-79.
3. Green AC, Williams GM, Logan V, Strutton GM. "Reduced Melanoma After Regular Sunscreen Use: Randomized Trial Follow-Up." Journal of Clinical Oncology. 2011;29(3):257-263.
4. Vestergaard ME, Macaskill P, Holt PE, Menzies SW. "Dermoscopy Compared with Naked Eye Examination for the Diagnosis of Primary Melanoma: A Meta-Analysis of Studies Performed in a Clinical Setting." British Journal of Dermatology. 2008;159(3):669-676.
5. Freeman K, Dinnes J, Chuchu N, et al. "Algorithm Based Smartphone Apps to Assess Risk of Skin Cancer in Adults: Systematic Review of Diagnostic Accuracy Studies." BMJ. 2020;368:m127.
6. Gandini S, Sera F, Cattaruzza MS, et al. "Meta-Analysis of Risk Factors for Cutaneous Melanoma." European Journal of Cancer. 2005;41(1):28-44; 41(1):45-60; 41(14):2040-2059.
7. Stang A, Jockel KH. "Does Skin Cancer Screening Save Lives? A Detailed Analysis of Mortality Time Trends in Schleswig-Holstein and Germany." Cancer. 2016;122(3):432-437.
8. Culp MB, Lunsford NB. "Melanoma Among Non-Hispanic Black Americans." Preventing Chronic Disease. 2019;16:180640.